Amgen, Inc. vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while State Street Real Estate Select Sector SPDR ETF trades at $44.45. The key difference: Amgen, Inc. pays a 2.77% dividend while State Street Real Estate Select Sector SPDR ETF pays none. Which is the better fit depends on your goals.
| AMGN | XLRE | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $45.36 |
52-Week Low | $271.18 | $40.01 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XLRE trades at $44.45, up 0.5% with neutral technical signals and mixed moving averages. The ETF shows resilience amid interest rate volatility, with real estate ETFs outperforming broader markets despite inflation concerns. Recent news highlights XLRE's low 0.08% expense ratio advantage over competitors and steady dividend distributions, though short interest in REITs edged higher in May.
Outlook remains balanced with potential from REIT sector recovery and diversification benefits, but faces headwinds from rising Treasury yields and inflation. The 3.4% dividend yield provides income appeal, though rate sensitivity and economic uncertainty warrant cautious monitoring of fundamental improvements in property markets.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →